We make CaP nanoparticles available to interested parties for evaluation in their vaccine programs and through collaborative research agreements or Material Transfer Agreements (MTA). The technology is also available for licensing under exclusive or non-exclusive terms.
To explore partnering and collaboration opportunities with CaPtivate, please send us an email at info@captivatepharma.com or call us at (215)298-3032.